Gene Therapy Latest News | Experimental Gene Therapy Studies

Roctavian’s Benefits Sustained for Up to 5 Years in Trial Patients

30 August 2021

Patients’ Priorities for Gene Therapy: Durability and Bleeding Control

28 July 2021

China OKs Hemophilia B Trial Testing BBM-H901 Gene Therapy

13 August 2021

Gene Therapy SPK-8011 Prevents Bleeds Up to 4 Years

23 July 2021

EMA OKs Biomarin’s New Application to Approve Roctavian
16 July 2021
Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A
09 July 2021
BioMarin Resubmits Roctavian Gene Therapy for EU Approval
30 June 2021
FDA Filing for UniQure, CSL's Haemophilia B Gene Therapy Planned for Early 2022
22 June 2021

I agree with the Terms and conditions and the Privacy policy

About

Supported by educational grants from BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc

Essential SSL